Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma

Aurélie Morin; Carmen Ruggiero; Estelle Robidel; Mabrouka Doghman-Bouguerra; Atze T. Das; Rémy Castellano; Emmanuelle Josselin; Judith Favier; Enzo Lalli

doi:10.18632/oncotarget.16909

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma

Aurélie Morin, Carmen Ruggiero, Estelle Robidel, Mabrouka Doghman-Bouguerra, Atze T. Das, Rémy Castellano, Emmanuelle Josselin, Judith Favier and Enzo Lalli _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:51050-51057. https://doi.org/10.18632/oncotarget.16909

Metrics: PDF 2195 views | HTML 3351 views | ?

Abstract

Aurélie Morin1,2, Carmen Ruggiero3,4, Estelle Robidel1,2, Mabrouka Doghman-Bouguerra3,4, Atze T. Das5, Rémy Castellano6, Emmanuelle Josselin6, Judith Favier1,2 and Enzo Lalli3,4

1Université Paris Descartes, Sorbonne Paris Cité, Paris, France

2Inserm UMR970, Paris Cardiovascular Research Centre, Paris, France

3Université Côte d’Azur, Valbonne, Sophia Antipolis, France

4Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, Sophia Antipolis, France

5Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

6Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France

Correspondence to:

Enzo Lalli, email: [email protected]

Keywords: adrenal cortex, cancer, cell lines, mouse models, xenografts

Abbreviations: ACC, adrenocortical carcinoma; EMT, epithelial-mesenchymal transition; GFP, green fluorescent protein; HES, hematoxylin-eosin-safran; SF-1, Steroidogenic Factor 1

Received: December 08, 2016 Accepted: March 15, 2017 Published: April 07, 2017

ABSTRACT

Adrenocortical carcinoma is a rare neoplasm with a poor prognosis. Very important advances have been made in the identification of the genetic determinants of adrenocortical carcinoma pathogenesis but our understanding is still limited about the mechanisms that determine cancer spread and metastasis. One major problem hindering preclinical experimentation for new therapies for adrenocortical carcinoma is represented by the lack of suitable animal models for metastatic disease. With the aim to overcome these limitations, in this study we tested several protocols in order to establish a mouse xenograft model of metastatic adrenocortical carcinoma. The most efficient method, based upon intrasplenic injection followed by splenectomy, produced metastases with high efficiency, whose development could be followed over time by bioluminescence measurements. We expect that the availability of this model will greatly improve the possibilities for preclinical testing of new treatments for advanced-stage disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16909

Publication Alerts

Research Papers:

Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma

Abstract